Literature DB >> 16940441

Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations.

C K Welt1, G Arason, J A Gudmundsson, J Adams, H Palsdóttir, G Gudlaugsdóttir, G Ingadóttir, W F Crowley.   

Abstract

CONTEXT: The phenotype of women with polycystic ovary syndrome (PCOS) is variable, depending on the ethnic background.
OBJECTIVE: The phenotypes of women with PCOS in Iceland and Boston were compared.
DESIGN: The study was observational with a parallel design.
SETTING: Subjects were studied in an outpatient setting. PATIENTS: Women, aged 18-45 yr, with PCOS defined by hyperandrogenism and fewer than nine menses per year, were examined in Iceland (n = 105) and Boston (n = 262). INTERVENTION: PCOS subjects underwent a physical exam, fasting blood samples for androgens, gonadotropins, metabolic parameters, and a transvaginal ultrasound. MAIN OUTCOME MEASURES: The phenotype of women with PCOS was compared between Caucasian women in Iceland and Boston and among Caucasian, African-American, Hispanic, and Asian women in Boston.
RESULTS: Androstenedione (4.0 +/- 1.3 vs. 3.5 +/- 1.2 ng/ml; P < 0.01) was higher and testosterone (54.0 +/- 25.7 vs. 66.2 +/- 35.6 ng/dl; P < 0.01), LH (23.1 +/- 15.8 vs. 27.6 +/- 16.2 IU/liter; P < 0.05), and Ferriman Gallwey score were lower (7.1 +/- 6.0 vs. 15.4 +/- 8.5; P < 0.001) in Caucasian Icelandic compared with Boston women with PCOS. There were no differences in fasting blood glucose, insulin, or homeostasis model assessment in body mass index-matched Caucasian subjects from Iceland or Boston or in different ethnic groups in Boston. Polycystic ovary morphology was demonstrated in 93-100% of women with PCOS in all ethnic groups.
CONCLUSIONS: The data demonstrate differences in the reproductive features of PCOS without differences in glucose and insulin in body mass index-matched populations. These studies also suggest that measuring androstenedione is important for the documentation of hyperandrogenism in Icelandic women. Finally, polycystic ovary morphology by ultrasound is an almost universal finding in women with PCOS as defined by hyperandrogenism and irregular menses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940441     DOI: 10.1210/jc.2006-1191

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

1.  Higher high-density lipoprotein cholesterol in African-American women with polycystic ovary syndrome compared with Caucasian counterparts.

Authors:  Kathryn W Koval; Tracy L Setji; Eric Reyes; Ann J Brown
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance.

Authors:  R Saxena; N A Georgopoulos; T J Braaten; A C Bjonnes; V Koika; D Panidis; C K Welt
Journal:  Hum Reprod       Date:  2015-04-22       Impact factor: 6.918

3.  Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome.

Authors:  Cindy Ta Pau; Candace C Keefe; Corrine K Welt
Journal:  Gynecol Endocrinol       Date:  2013-06       Impact factor: 2.260

4.  Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis.

Authors:  Unnur Styrkarsdottir; Hannes Helgason; Asgeir Sigurdsson; Gudmundur L Norddahl; Arna B Agustsdottir; Louise N Reynard; Amanda Villalvilla; Gisli H Halldorsson; Aslaug Jonasdottir; Audur Magnusdottir; Asmundur Oddson; Gerald Sulem; Florian Zink; Gardar Sveinbjornsson; Agnar Helgason; Hrefna S Johannsdottir; Anna Helgadottir; Hreinn Stefansson; Solveig Gretarsdottir; Thorunn Rafnar; Ina S Almdahl; Anne Brækhus; Tormod Fladby; Geir Selbæk; Farhad Hosseinpanah; Fereidoun Azizi; Jung Min Koh; Nelson L S Tang; Maryam S Daneshpour; Jose I Mayordomo; Corrine Welt; Peter S Braund; Nilesh J Samani; Lambertus A Kiemeney; L Stefan Lohmander; Claus Christiansen; Ole A Andreassen; Olafur Magnusson; Gisli Masson; Augustine Kong; Ingileif Jonsdottir; Daniel Gudbjartsson; Patrick Sulem; Helgi Jonsson; John Loughlin; Thorvaldur Ingvarsson; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2017-03-20       Impact factor: 38.330

5.  Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study.

Authors:  Gwinnett Ladson; William C Dodson; Stephanie D Sweet; Anthony E Archibong; Allen R Kunselman; Laurence M Demers; Nancy I Williams; Ponjola Coney; Richard S Legro
Journal:  Fertil Steril       Date:  2011-07       Impact factor: 7.329

6.  Gene variants associated with age at menopause are also associated with polycystic ovary syndrome, gonadotrophins and ovarian volume.

Authors:  R Saxena; A C Bjonnes; N A Georgopoulos; V Koika; D Panidis; C K Welt
Journal:  Hum Reprod       Date:  2015-05-20       Impact factor: 6.918

7.  Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes.

Authors:  R Saxena; C K Welt
Journal:  Acta Diabetol       Date:  2012-03-03       Impact factor: 4.280

8.  Relationship between polycystic ovary syndrome and ancestry in European Americans.

Authors:  Andrew C Bjonnes; Richa Saxena; Corrine K Welt
Journal:  Fertil Steril       Date:  2016-09-22       Impact factor: 7.329

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Overexpression of Lnk in the Ovaries Is Involved in Insulin Resistance in Women With Polycystic Ovary Syndrome.

Authors:  Meihua Hao; Feng Yuan; Chenchen Jin; Zehong Zhou; Qi Cao; Ling Xu; Guanlei Wang; Hui Huang; Dongzi Yang; Meiqing Xie; Xiaomiao Zhao
Journal:  Endocrinology       Date:  2016-07-26       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.